Drug Therapy for Rhythm and Rate Control in Atrial Fibrillation

Chapter
Part of the Current Cardiovascular Therapy book series (CCT)

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice. It is not a benign disease because is associated to a significant increase in mortality and morbidity. Thus, being AF a potentially dangerous arrhythmia, it seems logical to use antiarrhythmic strategies to avoid, or at least control, this rhythm disturbance [1, 2].

Keywords

Digoxin Verapamil Amiodarone Metoprolol Diltiazem 

References

  1. 1.
    Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J. 2006;27:1979–2030.PubMedCrossRefGoogle Scholar
  2. 2.
    Camm JA, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, DeSutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kolh P, LeHeuzey JY, Ponikowski P, Rutten FR. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369–429.PubMedCrossRefGoogle Scholar
  3. 3.
    Wyse DG, Waldo AL, DiMarco JP. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Corley SD, Epstein AE, DiMarco JP. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1509.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsadok MA, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Pilote L. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126:2680–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Camm AJ, Capucci A, Hohnloser S, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch GN. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.PubMedGoogle Scholar
  8. 8.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.PubMedCrossRefGoogle Scholar
  11. 11.
    Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–607.PubMedCrossRefGoogle Scholar
  12. 12.
    Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.PubMedCrossRefGoogle Scholar
  13. 13.
    Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Healy JS, Baranchuk A, Crystal E. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832.CrossRefGoogle Scholar
  15. 15.
    Disertori M, Latini R, Barlera S. Valsartan for the prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606.PubMedCrossRefGoogle Scholar
  16. 16.
    Liu T, Li L, Karantzopoulos PO. Statin use in the development of atrial fibrillation: asystematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126:160.PubMedCrossRefGoogle Scholar
  17. 17.
    Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828.PubMedCrossRefGoogle Scholar
  18. 18.
    AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.CrossRefGoogle Scholar
  19. 19.
    Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Josep Guindo Soldevila
    • 1
  • Antoni Martinez-Rubio
    • 2
  1. 1.Cardiology ServiceHospital Parc Tauli de SabadellSabadell, BarcelonaSpain
  2. 2.Department of CardiologyUniversity Hospital of SabadellSabadell, BarcelonaSpain

Personalised recommendations